Inactive Instrument

Press Releases Enzon Pharmaceuticals Inc Nasdaq

Equities

US2939041081

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 20	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ENZON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-05	AQ
ENZON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-02-16	AQ
ENZON PHARMACEUTICALS, INC. : Other Events (form 8-K)	23-01-06	AQ
ENZON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-09	AQ
ENZON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-04	AQ
ENZON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	22-06-15	AQ
ENZON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-04-26	AQ
ENZON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	22-02-25	AQ
ENZON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	21-11-05	AQ
ENZON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	21-08-05	AQ
Enzon Pharmaceuticals : CONTINENTAL STOCK TRANSFER & TRUST COMPANY (Form 8-K)	21-06-08	PU
ENZON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	21-06-08	AQ
ENZON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	21-05-04	AQ
ENZON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	21-02-23	AQ
Enzon Pharmaceuticals : CEO Andrew Rackear to Retire, Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO	21-01-05	AQ
ENZON PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	21-01-04	AQ
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO	21-01-04	GL
ENZON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	20-12-21	AQ
ENZON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	20-11-09	AQ
Enzon Pharmaceuticals : Announces Results of Rights Offering	20-10-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Enzon Pharmaceuticals Inc Nasdaq

Equities

US2939041081

Press Releases

Filters